Masimo’s lawsuit against Apple continues — along with the posturing and gesticulation from its CEO, Joe Kiani. Where he sees himself as some kind of David fighting Apple’s Goliath, he speaks about the strength of Masimo’s products — and the weakness of his legal rivals.
In his most recent interview with Bloomberg, Kiani claims that Apple’s Blood Oxygen sensors in the Apple Watch Ultra 2 and Series 9 are inaccurate, adding that he “really feels that consumers are better off without it.”
Instead, he says, users should buy Masimo’s pulse oximeter, as it takes constant measurements.
The Apple Watch legal trouble continues
In an effort to placate the legal proceedings, Apple has removed the software in the Apple Watch Series 9 and Ultra 2 models that use the blood oxygen reading equipment.
Kiani, however, doesn’t appear to be finished, continuing that “Apple is masquerading what they are offering to consumers as a reliable, medical pulse oximeter, even though it is not.” As always, the man from Masimo has strong words.
Apple has replied. The firm claims that the blood oxygen sensor is accurate, and that, in essence, Kiani isn’t telling the truth. The difference between the two oximeters is that Apple’s takes a measurement twice a day, and when the user chooses to double-check. The Masimo device takes a reading throughout the day, for what Masimo claims is ‘a more accurate reading’.
Apple argues that accuracy isn’t about how long the reading is, but how it measures up against ‘high-quality reference data’. Even so, Kiani goes on to say that Apple hasn’t reached out to him about the case — something which Apple claims is false, noting that it has a meeting with Masimo in its diary: And that mediation has already taken place.
Of 17 of Masimos patents, Apple claims that 15 have been invalidated — the rest of the ITC case pertains to the other 2.
